US Patent

US9561229 — Emulsion formulations of aprepitant

Method of Use · Assigned to Heron Therapeutics LLC · Expires 2035-09-18 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel pharmaceutical formulations of aprepitant, including those with dexamethasone sodium phosphate, for parenteral administration to treat emesis caused by cancer chemotherapy.

USPTO Abstract

Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2161 — Emend
U-3440 — Emend

Patent Metadata

Patent number
US9561229
Jurisdiction
US
Classification
Method of Use
Expires
2035-09-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Heron Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.